Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$0.11
+2.0%
$0.09
$0.06
$0.24
$8.53M0.36116,292 shs18,226 shs
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
$0.73
-0.6%
$3.47
$0.50
$2.67
$12.54M1.833.78 million shs27,836 shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.40
+1.1%
$4.42
$3.03
$14.80
$4.00M1.27138,037 shs18,730 shs
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
$0.40
$0.40
$0.13
$1.04
N/AN/AN/AN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
+1.95%+14.90%+33.60%+14.90%-32.41%
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
+2.01%+0.52%-4.01%+13.28%-83.23%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
+1.64%+1.13%-7.76%+16.87%-16.35%
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.3539 of 5 stars
0.03.00.00.02.50.00.0
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00
N/AN/AN/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
0.00
N/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00
N/AN/AN/A
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$30K284.22$0.01 per share10.75$0.04 per share2.87
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
$10K1,253.96N/AN/A$1.33 per share0.55
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$180K22.24N/AN/A$2.67 per share1.65
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
$1.86MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$780K-$0.01N/AN/AN/A-22.19%-1.28%8/6/2025 (Estimated)
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
-$8.35MN/A0.00N/A-230.34%-122.20%-110.61%N/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$4.71M-$4.59N/AN/AN/A-145.92%-129.20%8/13/2025 (Estimated)
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
-$9.87M-$2.21N/AN/A-356.89%N/A-107.24%N/A

Latest ENZN, SNCA, TTNP, and VODG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
5/9/2025Q1 2025
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A-$0.01N/A-$0.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/AN/AN/AN/AN/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
82.17
82.17
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
N/A
14.96
14.96
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
7.73
7.73
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
N/A
0.04
0.03

Institutional Ownership

CompanyInstitutional Ownership
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
5.24%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
N/A

Insider Ownership

CompanyInsider Ownership
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.40%
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
2.11%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.72%
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
27.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A74.21 million73.92 millionNot Optionable
Seneca Biopharma, Inc. stock logo
SNCA
Seneca Biopharma
717.30 millionN/ANot Optionable
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
10910,000907,000Optionable
Vitro Diagnostics stock logo
VODG
Vitro Diagnostics
2N/AN/ANot Optionable

Recent News About These Companies

FDA Brings Lab Tests Under Its Oversight

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enzon Pharmaceuticals stock logo

Enzon Pharmaceuticals OTCMKTS:ENZN

$0.11 +0.00 (+1.95%)
As of 07/3/2025 11:48 AM Eastern

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Seneca Biopharma stock logo

Seneca Biopharma NASDAQ:SNCA

Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

$4.40 +0.05 (+1.15%)
As of 07/3/2025 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

Vitro Diagnostics stock logo

Vitro Diagnostics OTCMKTS:VODG

$0.40 0.00 (0.00%)
As of 10/15/2020

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.